Blood transfusions or erythropoietin stimulating agents (ESA) are both successful in the treatment of anaemia, but as these modalities significantly increase the risk of recurrence and even mortality, they should be given with restraint [31]. This evidence concerns the gene EPO and anemia (phenotype).